Key result
Nebivolol improved regulatory-adaptive status, exercise tolerance, and quality of life more than bisoprolol and sotalol in patients with ventricular arrhythmias over 24 weeks.
Why the study?
Optimizing drug therapy for ventricular arrhythmias remains relevant, and antiarrhythmic drugs may exert multidirectional effects on functional state.
Does nebivolol improve functional state compared to bisoprolol or sotalol in patients with ventricular arrhythmias and hypertension or coronary heart disease?
RCT (n=120)
randomized
Does nebivolol improve functional state compared to bisoprolol or sotalol in patients with ventricular arrhythmias and hypertension or coronary heart disease?
Nebivolol may be preferable to bisoprolol or sotalol in patients with ventricular arrhythmias and hypertension due to superior improvements in functional state and quality of life.
May support nebivolol preference in ventricular arrhythmia patients; leaves open randomized confirmation.
Sudden cardiac death and the heaviest arrhythmic events are connected to ventricular arrhythmias (VA). The issue of optimization of drug therapy for VA remains relevant. Given the possible multidirectional effects of antiarrhythmic drugs on the functional state, in order to determine the effectiveness of pharmacotherapy in patients with VA it is advisable to use a stepwise integrated approach. Aim. Compare the effects of bisoprolol, nebivolol and sotalol on the functional state of patients with VA. Materials and methods. 120 patients with VA of grade IIV based on the В. Lown grading system, III groups based on J. Bigger grading system against the background of essential hypertension or its combination with coronary heart disease took part in the research, they were randomized into three groups for treatment with bisoprolol, nebivolol and sotalol. As part of combination therapy, patients were administered lisinopril, and if indicated, acetylsalicylic acid, atorvastatin. Initially and after 24 weeks of therapy the following was done: quantitative assessment of regulatory-adaptive status by cardio-respiratory synchronism test, treadmill test, six-minute walk test, subjective assessment of quality of life, all-day monitoring of blood pressure and electrocardiogram. Results. With comparable hypotensive and antiarrhythmic effects, therapy with nebivolol had a positive effect on the regulatory-adaptive status, had a better effect on exercise tolerance in comparison with bisoprolol and sotalol, more improved the quality of life, in comparison with bisoprolol and sotalol. Conclusion. In patients with VA against the background of essential hypertension or its combination with coronary heart disease as part of combination therapy the use of nebivolol may be preferable to bisoprolol or sotalol due to a more pronounced positive effect on the functional state.
No takes yet. Share an insight, caveat, or question.
Shubitidze et al. (2021) conducted an RCT in Ventricular arrhythmias with essential hypertension (n=120). Nebivolol vs. Bisoprolol and sotalol was evaluated on Functional state (regulatory-adaptive status, exercise tolerance, quality of life). Nebivolol improved regulatory-adaptive status, exercise tolerance, and quality of life more than bisoprolol and sotalol in patients with ventricular arrhythmias over 24 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: